- Moderna Inc (NASDAQ:MRNA) would set up a manufacturing facility in Kenya, its first in Africa, to produce messenger RNA (mRNA) vaccines, including COVID-19 shots.
- Moderna expects to invest about $500 million in the Kenyan facility and supply as many as 500 million doses of mRNA vaccines to the continent each year.
- It also has plans to start filling doses of its COVID vaccine in Africa as early as 2023.
- Related: Moderna To Build mRNA Vaccine Factory In Africa.
- The company said that Moderna's Kenyan facility would manufacture drug substances and could be expanded to include fill/finish and packaging capabilities.
- Moderna's COVID vaccine brought in $17.7 billion in sales in 2021.
- Also See: Arbutus Hits Moderna With New Suit Claiming COVID-19 Vaccine Patent(s).
- The company is developing several other vaccines based on mRNA technology, including respiratory syncytial virus, HIV, and shingles.
- Price Action: MRNA shares are down 6.35% at $127.80 during the market session on the last check Monday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Moderna To Set Up mRNA Vaccine Manufacturing Facility In Kenya
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks